Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus

Author: Benzinga Newsdesk | September 08, 2021 08:05am

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc. ("Astria" or the "Company"). The name Astria originates from the Greek word for star, reflecting the Company's commitment to having patients serve as guiding stars. Astria's mission is to bring hope with life-changing therapies to patients and families. Astria expects to begin trading under the new ticker symbol "ATXS" on the Nasdaq Global Select Market at market open on September 9, 2021, and the new website, www.astriatx.com, launched today containing information about STAR-0215, HAE, and a new corporate presentation.

"The name Astria embodies our commitment to put patients first in all that we do," said Jill C. Milne, Ph.D., Chief Executive Officer of Astria Therapeutics. "Following the acquisition of Quellis earlier this year, our company is focused on tackling the debilitating disease hereditary angioedema, with the broader goal of addressing the unmet needs of patients with rare and niche allergic and immunological diseases. We are advancing STAR-0215 as a differentiated and potentially the most patient-friendly preventative treatment option with dosing once every three months or longer. We are proud to launch Astria Therapeutics and bring our team's combination of experience, passion, and compassion to our future vision and our commitment to patients and their families."

Posted In: CATB